Granules India`s Q1 profit nearly triples on strong demand
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended June 30, 2024.nnGlenmark Life Sciences has posted net profit of Rs. 111.483 crores for the period ended June 30, 2024 as against net profit of Rs. 97.937 crores for the period ended March 31, 2024. The company posted net profit of Rs.135.450 crores for the period ended June 30, 2023.
The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastrointestinal therapies. According to market researcher Pharmarack, these therapies saw double-digit growth compared to June 2023.
Glenmark Life Sciences Reports 5.6% Revenue Growth, 30.1% EBITDA Margin
Nirma Limited acquires majority stake in Glenmark Life Sciences
Nirma acquires majority stake in Glenmark Life Sciences
Glenmark Life Sciences Reports 5.9% Revenue Growth, 14.6% EBITDA Growth
Glenmark Life Sciences Limited (GLS), a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced the signing of a Master Supply Agreement (MSA) with a Japanese innovator pharmaceutical company with global presence in Europe, United States and Asia. Under the aegis of the Master Supply Agreement, Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator.
Glenmark launches triple-drug combo for type 2 diabetes
Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in the American market. nnnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-to-market-generic-diabetes-drug/articleshow/102302377.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst